Cargando…
Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function
OBJECTIVE: To investigate the effect of 4 weeks of treatment with liraglutide on insulin dose and glycemic control in type 1 diabetic patients with and without residual β-cell function. RESEARCH DESIGN AND METHODS: Ten type 1 diabetic patients with residual β-cell function (C-peptide positive) and 1...
Autores principales: | Kielgast, Urd, Krarup, Thure, Holst, Jens Juul, Madsbad, Sten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3120168/ https://www.ncbi.nlm.nih.gov/pubmed/21593296 http://dx.doi.org/10.2337/dc11-0096 |
Ejemplares similares
-
Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function
por: Kielgast, Urd, et al.
Publicado: (2011) -
Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
por: Holst, Jens J., et al.
Publicado: (2011) -
Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report
por: Knop, Filip K, et al.
Publicado: (2014) -
Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease
por: Anholm, Christian, et al.
Publicado: (2019) -
Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes
por: Hansen, Christian Stevns, et al.
Publicado: (2019)